CTLA4 and neoplasm: Combined therapeutic strategies from preclinical [115,117,219] and clinical studies [14] have shown that anti-PD-1 plus anti-CTLA-4 (nivolumab and ipilimumab) treatments elicit stronger immune stimulation in stage IV melanoma than monotherapy alone, resulting in a favorable anti-tumor immune response.